Please assess the completion status of the following clinical trial:

Trial Title: Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signature of informed consent~* At least 18 years old~* Patients on their 1st ARV treatment consisting on 2 NRTIs + 1 third agent for at least 1 year~* Undetectable viral load for at least 6 months prior to inclusion in the study (VL\<50 c/mL in 2 determinations 6 months apart; blips are not allowed).~* Requirement of ARV treatment change due to toxicity, intolerance or simplification.~* Clinically stable.~Exclusion Criteria:~* Pregnant women or women who plan to get pregnant during the study.~* Breast feeding~* History of change of any ARV treatment component for any reason 4 months prior to the inclusion in the trial~* History of ARV treatment change due to virological failure~* History of confirmed virological failure defined as one single VL \>400 c/mL or at least 2 VL between 50 and 400 c/mL one year after an indetectable VL was achieved.~* Absence of HIV genotype prior to ARV treatment initiation.~* Resistance mutation to any of the study drugs (ATV, RTV, 3TC)~* HBV infection.~* History of toxicity or intolerance to ATV, RTV or 3TC.~* Gilbert's syndrome.~* Use of contraindicated drugs.~* Lab abnormalities grade 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATV/r+3TC (Type: EXPERIMENTAL): Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
- ATV/r+2 NRTIs (Type: ACTIVE_COMPARATOR): Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).